exemestane + bicalutamide

Exemestane + bicalutamide is a combination of two small molecule drugs, each with distinct mechanisms of action targeting hormone-dependent cancers. Exemestane is an aromatase inhibitor that irreversibly blocks the enzyme aromatase, leading to decreased estrogen production. It is primarily used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women. Bicalutamide is a nonsteroidal antiandrogen that acts as an antagonist at androgen receptors, blocking the effects of androgens such as testosterone and dihydrotestosterone; it is mainly indicated for prostate cancer therapy, often in combination with other agents or surgical castration[1][5][7]. The rationale for combining these agents would be to simultaneously suppress both estrogenic and androgenic hormonal pathways, potentially relevant in certain hormone-driven malignancies or research settings.